NCT02826525View on ClinicalTrials.gov

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

July 18, 2016

Primary Completion Date

October 11, 2019

Study Completion Date

October 11, 2019

Conditions

T2DM With NAFLD

Interventions

DRUG

AZD4076

Investigational product

DRUG

Placebo

Control

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY